Coamorphous and cocrystal drug delivery systems provide
attractive
crystal engineering strategies for improving the solubilities, dissolution
rates, and oral bioavailabilities of poorly water-soluble drugs. Polymeric
additives have often been used to inhibit the unwanted crystallization
of amorphous drugs. However, the transformation of a coamorphous phase
to a cocrystal phase in the presence of polymers has not been fully
elucidated. Herein, we investigated the effects of low concentrations
of the polymeric excipients poly(ethylene oxide) (PEO) and poly(vinylpyrrolidone)
(PVP) on the growth of carbamazepine–celecoxib (CBZ-CEL) cocrystals
from the corresponding coamorphous phase. PEO accelerated the growth
rate of the cocrystals by increasing the molecular mobility of the
coamorphous system, while PVP had the opposite effect. The coamorphous
CBZ-CEL system exhibited two anomalously fast crystal growth modes:
glass-to-crystal (GC) growth in the bulk and accelerated crystal growth
at the free surface. These two fast growth modes both disappeared
after doping with PEO (1–3% w/w) but were retained in the presence
of PVP, indicating a potential correlation between the two fast crystal
growth modes. We propose that the different effects of PEO and PVP
on the crystal growth modes arose from weaker effects of the polymers
on cocrystallization at the surface than in the bulk. This work provides
a deep understanding of the mechanisms by which polymers influence
the cocrystallization kinetics of a multicomponent amorphous phase
and highlights the importance of polymer selection in stabilizing
coamorphous systems or preparing cocrystals via solid-based methods.